Cosmo Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Cosmo Pharmaceuticals has been growing earnings at an average annual rate of 59.3%, while the Pharmaceuticals industry saw earnings declining at 1.7% annually. Revenues have been growing at an average rate of 13.3% per year. Cosmo Pharmaceuticals's return on equity is 0.3%, and it has net margins of 1.2%.
Key information
59.3%
Earnings growth rate
59.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 13.3% |
| Return on equity | 0.3% |
| Net Margin | 1.2% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cosmo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 97 | 1 | 29 | 18 |
| 30 Sep 23 | 100 | 6 | 24 | 17 |
| 30 Jun 23 | 104 | 11 | 20 | 16 |
| 31 Mar 23 | 103 | 14 | 20 | 16 |
| 31 Dec 22 | 102 | 17 | 20 | 15 |
| 30 Sep 22 | 90 | 26 | 16 | 13 |
| 30 Jun 22 | 78 | 35 | 13 | 11 |
| 31 Mar 22 | 72 | 28 | 12 | 11 |
| 31 Dec 21 | 65 | 22 | 11 | 11 |
| 30 Sep 21 | 64 | 6 | 14 | 13 |
| 30 Jun 21 | 63 | -11 | 17 | 14 |
| 31 Mar 21 | 62 | -9 | 18 | 14 |
| 31 Dec 20 | 61 | -8 | 19 | 14 |
| 30 Sep 20 | 64 | -7 | 21 | 14 |
| 30 Jun 20 | 67 | -7 | 24 | 15 |
| 31 Mar 20 | 65 | -16 | 30 | 15 |
| 31 Dec 19 | 62 | -24 | 35 | 15 |
| 30 Sep 19 | 56 | -28 | 39 | 14 |
| 30 Jun 19 | 50 | -31 | 42 | 14 |
| 31 Mar 19 | 58 | -24 | 46 | 12 |
| 31 Dec 18 | 66 | -18 | 51 | 10 |
| 30 Sep 18 | 69 | -20 | 52 | 10 |
| 30 Jun 18 | 73 | -23 | 54 | 9 |
| 31 Mar 18 | 70 | -28 | 50 | 9 |
| 31 Dec 17 | 68 | -32 | 46 | 9 |
| 30 Sep 17 | 68 | -18 | 38 | 9 |
| 30 Jun 17 | 69 | -4 | 31 | 9 |
| 31 Mar 17 | 69 | 8 | 23 | 8 |
| 31 Dec 16 | 68 | 19 | 16 | 7 |
| 30 Sep 16 | 70 | 18 | 13 | 10 |
| 30 Jun 16 | 72 | 16 | 10 | 13 |
| 31 Mar 16 | 66 | 132 | 16 | 18 |
| 31 Dec 15 | 61 | 248 | 23 | 23 |
| 30 Sep 15 | 60 | 241 | 26 | 23 |
| 30 Jun 15 | 59 | 234 | 29 | 23 |
| 31 Mar 15 | 69 | 154 | 23 | 21 |
| 31 Dec 14 | 80 | 73 | 17 | 19 |
| 30 Sep 14 | 76 | 78 | 14 | 20 |
| 30 Jun 14 | 72 | 82 | 10 | 21 |
| 31 Mar 14 | 65 | 75 | 9 | 19 |
| 31 Dec 13 | 57 | 69 | 8 | 18 |
| 30 Sep 13 | 51 | 66 | 7 | 15 |
| 30 Jun 13 | 45 | 64 | 7 | 12 |
Quality Earnings: 0RGI has a large one-off gain of €1.3M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 0RGI's current net profit margins (1.2%) are lower than last year (16.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RGI has become profitable over the past 5 years, growing earnings by 59.3% per year.
Accelerating Growth: 0RGI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0RGI had negative earnings growth (-93.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.8%).
Return on Equity
High ROE: 0RGI's Return on Equity (0.3%) is considered low.